TVI-BRAIN-1 Overview

TVAX Biomedical is a mid/late clinical stage company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company has received Fast Track Designation from the FDA for their clinical study in glioblastoma and a $2 million grant from the FDA Office of Orphan Products. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated.  The power of T cells is their demonstrated ability to kill cancer cells, including cancer stem cells, and cause significant numbers of objective clinical responses in treated patients.

The company’s lead candidate, TVI-Brain-1, is focused on treating glioblastoma (a form of brain cancer) and is supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies.  TVAX is initiating a Phase 2b study in newly diagnosed surgically resectable O6-methylguanine methyltransferase negative (MGMT unmethylated) glioblastoma patients in 2023. The clinical study will be conducted at academic and corporate hospital clinical sites around the US. If you are interested in additional information, please contact TVAX at info@tvaxbiomedical.com.